Bank of America Lowers Kymera Therapeutics (NASDAQ:KYMR) Price Target to $44.00
Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its price objective lowered by Bank of America from $47.00 to $44.00 in a report published on Monday morning,Benzinga reports. Bank of America currently has a neutral rating on the stock. Other research analysts have also recently issued reports about the stock. Citigroup initiated coverage on shares of […]
Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its price objective lowered by Bank of America from $47.00 to $44.00 in a report published on Monday morning,Benzinga reports. Bank of America currently has a neutral rating on the stock. Other research analysts have also recently issued reports about the stock. Citigroup initiated coverage on shares of […]
